With the arrival of the new Wegovy pill, patients now have another option. The once-daily pill contains the same active ingredient as the well-known weekly Wegovy injection, offering an effective alternative for suitable patients who prefer not to use needles.

What is the Wegovy pill?

The new tablet contains oral semaglutide, a GLP-1 receptor agonist that works by mimicking a naturally occurring hormone involved in appetite regulation.

Like the injectable version, it helps to:

– Reduce hunger

– Increase feelings of fullness

– Slow stomach emptying

– Reduce food cravings

– Support sustainable weight loss alongside lifestyle changes

Following successful clinical trials, the oral formulation has now been approved in several countries, including the UK, becoming the first licensed GLP-1 tablet specifically for weight management. Clinical studies demonstrated average weight loss of around 14–17% of body weight over 64 weeks, comparable to injectable Wegovy when taken consistently

How does it compare with Wegovy injections?

Although they contain the same active ingredient (semaglutide), there are several practical differences.

For many patients, the convenience of avoiding injections is appealing. However, the tablet requires stricter daily timing to ensure adequate absorption.

Success often comes down less to the medication itself and more to choosing the option that best fits an individual’s lifestyle.

Does the pill work as well?

One of the biggest surprises from the clinical trials is just how effective the oral formulation has been.

When patients adhered to treatment as prescribed, average weight loss reached approximately 16.6% of body weight, very similar to results seen with injectable Wegovy. Around one in three participants lost at least 20% of their starting weight.

As with all GLP-1 medications, outcomes vary depending on:

– Starting weight

– Diet

– Physical activity

– Sleep

– Medical conditions

– Long-term adherence

Medication should always be viewed as one component of a comprehensive weight management programme rather than a standalone solution.

Are the side effects different?

Not significantly.

Both the tablet and injection contain semaglutide, so the side effect profile is broadly the same.

The most common include:

– Nausea

– Constipation

– Diarrhoea

– Indigestion

– Vomiting

– Reduced appetite

These symptoms are usually temporary and improve as the body adjusts during gradual dose escalation.

For this reason, careful medical supervision and personalised dose titration remain essential.

Which treatment is right for you?

There is no universal “best” weight loss medication. The right choice depends on several factors, including:

– Your medical history

– Current medications

– Weight loss goals

– Previous experience with GLP-1 treatments

– Confidence with self-injection

– Individual response to treatment

Some patients prefer the simplicity of one weekly injection. Others value the convenience of avoiding needles altogether, even if that means taking a tablet every morning.

A thorough assessment allows treatment to be tailored to each patient’s needs rather than taking a one-size-fits-all approach.

A personalised approach to medical weight loss

Modern weight management has moved well beyond simply prescribing medication.

At Dr Sophia Khalique Associates, every patient undergoes a detailed medical assessment before treatment begins.

We review your health history, metabolic risk factors and weight loss goals before recommending the most appropriate treatment, whether that is the new Wegovy tablet, weekly injections such as Wegovy or Mounjaro, or an alternative evidence-based strategy.

Medication works best when combined with expert medical oversight, nutritional guidance, realistic goal setting and ongoing follow-up to maximise results while minimising side effects.

Schedule a Weight Management Consultation

If you’re considering medical treatment for weight loss and would like expert advice on whether the new Wegovy tablet or injectable therapies are right for you, our experienced clinicians can provide a personalised assessment and create a treatment plan tailored to your individual health goals.

The post IS ORAL WEIGHT LOSS MEDICATION BETTER THAN WEEKLY INJECTIONS? appeared first on Dr Sophia Khalique.

In contrast, Novo Nordisk has kept UK pricing for Ozempic (semaglutide) relatively stable. So what’s the difference between these two increasingly popular weight loss and diabetes medications? 

Ozempic vs. Mounjaro: What’s the Difference? 

Ozempic launched in the UK in 2019 as a treatment for type 2 diabetes. It quickly gained traction due to its noticeable weight loss effects. Novo Nordisk then introduced Wegovy, a higher-dose version of semaglutide approved specifically for weight management, and Rybelsus, an oral tablet formulation of semaglutide. All three share the same active ingredient: semaglutide, a GLP-1 receptor agonist.

Mounjaro was approved in the UK in 2023 and uses a newer molecule called tirzepatide. It acts on both GLP-1 and GIP receptors, making it more effective in its metabolic action. This dual mechanism enhances insulin sensitivity, suppresses appetite, and increases fat oxidation. In my experience, Mounjaro often results in more weight loss than Ozempic with fewer side effects.

On average, people using semaglutide (Ozempic or Wegovy) lose about 15% of their body weight over one year. Mounjaro users can see reductions of up to 20% or more, according to the SURMOUNT trials. This makes it particularly attractive to patients aiming for more aggressive results. 

Ozempic vs Mounjaro: What’s Safer? 

One major point of difference is cardiovascular outcome data. Semaglutide has more established data for reducing the risk of major adverse cardiovascular events (MACE), regardless of weight loss.

Mounjaro shows promise but it’s newer and long-term cardiovascular benefits are still under active investigation. Results from the SURPASS-CVOT trial are expected in 2025. I think it’s highly likely we will learn Mounjaro is as good as Ozempic. Until then, some patients prefer semaglutide given the greater level of experience and data. 

Ozempic vs Mounjaro: What Causes More Side Effects? 

Side effect profiles for both drugs are similar, most commonly involving nausea, constipation, or diarrhoea, especially during dose escalation. I see patients report fewer side effects with tirzepatide, but this varies.

For all patients, I start with a lower dose and gradually increase it under supervision. Explore our guide to GLP-1 medications and how they support longevity.

Ozempic vs Mounjaro: Maintenance and Microdosing 

Many patients build up to a higher dose for weight loss and then transition to a “maintenance dose” to sustain their results. This is commonly referred to as microdosing. Both semaglutide and tirzepatide are used in this way, although it’s an off-label approach.

For those who have reached their target weight, a lower maintenance dose may continue to offer metabolic support without the side effects (and cost!) of full-dose therapy. This strategy can be tailored during follow-ups and monitoring. 

Tablet Options: Rybelsus vs Mounjaro vs Ozempic / Wegovy 

If injections are a concern, Rybelsus offers an alternative. It delivers semaglutide in tablet form, making it ideal for people who have an aversion to needles. There is no oral formulation of tirzepatide right now.

Patients with GI sensitivity or skin reactions to injectable medications may also find oral GLP-1 agonists more comfortable, though the overall benefit in weight loss may vary. Rybelsus is taken once daily, and timing it correctly in a fasted state is important for optimal absorption. 

Ozempic vs Mounjaro: Costs 

Currently, Mounjaro is significantly more expensive than Ozempic / Wegovy, which are more widely available and supported by longer-term experience. For many, the price difference becomes a deciding factor, especially if tolerability and weight loss results are similar.

In terms of long-term use, semaglutide is generally seen as safer, simply because it has been studied longer. Some patients starting with tirzepatide eventually switch to semaglutide for maintenance due to comfort with the data, cost, or insurance/availability issues.

In my practice I often help patients carefully switch from one medication to the other and have experience of helping patients do this due to side-effects, supply or cost issues. For a deeper understanding of metabolic health and anti-ageing strategies, explore our Longevity Medicine blog.

What about new alternatives like Retatrutide and Orforglipron? 

Retatrutide, a next-generation triple agonist, targets GLP-1, GIP, AND glucagon receptors. It’s shown even better weight loss potential than Mounjaro in early trials — with some patients losing over 24% of their body weight. However, it’s not yet been officially released.

Eli Lilly’s oral GLP-1 receptor agonist, Orforglipron, offers a tablet-based alternative to injections. While promising for convenience, early data suggests weight loss results are more modest compared to injected semaglutide (Ozempic) or tirzepatide (Mounjaro). 

Final Thoughts 

Both Ozempic and Mounjaro are transformative options for managing metabolic health and supporting longevity. The choice between them should be guided by medical advice, personal goals, side effect profile, and budget.

Whether starting on one or considering a switch, it’s essential to work closely with a doctor experienced in longevity medicine, peptide therapy, and weight optimisation.

Book a consultation at Dr Sophia Khalique & Associates to explore doctor-led treatment options tailored to your goals.

The post Price Rise, Weight Loss: Mounjaro vs. Ozempic  appeared first on Dr Sophia Khalique.